Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety, Pharmacokinetics (PK) and Efficacy of AI-061, A 1:1 Co-formulation of AI-025 (Anti-PD-1) and ONC-392 (Anti-CTLA-4) Antibodies in Advanced Solid Tumors: An Open-Label Phase 1 Study

NCT05858736 is registered in ClinicalTrials.gov with OncoC4, Inc. as lead sponsor.

NCT NCT05858736
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05858736 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety, Pharmacokinetics (PK) and Efficacy of AI-061, A 1:1 Co-formulation of AI-025 (Anti-PD-1) and ONC-392 (Anti-CTLA-4) Antibodies in Advanced Solid Tumors: An Open-Label Phase 1 Study
Lead sponsor
OncoC4, Inc.
Phase
Phase 1
Overall status
Completed
Start date
July 11, 2023
Completion date
July 31, 2026
Enrollment
18 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

anal cancer, bile duct cancer, bladder cancer, cervical cancer, colorectal cancer, endometrial cancer, esophageal cancer, fallopian tube cancer, gastric cancer, gastroesophageal-junction cancer, head and neck squamous cell carcinoma, hepatocellular carcinoma, high grade serous adenocarcinoma of ovary, melanoma, non small cell lung cancer, primary peritoneal carcinoma, renal cell carcinoma